Abstract
The term “neuroacanthocytosis” (NA) is used for a spectrum of neurological disorders in which there are thorny red blood cells. While NA historically referred to disorders of lipoprotein absorption, we have promoted it as an overarching term for a group of basal ganglia disorders, with specific reference to two diseases that we defined as “core” NA syndromes. “Neuroacanthocytosis” has also been used to refer to a specific, now genetically-defined disease, otherwise known as “chorea-acanthocytosis”. These various usages have resulted in diagnostic confusion, and in a number of cases have quite likely prevented the pursuance of precise, molecular, diagnosis. Disease nomenclature is an everevolving field, especially in the current era of expanding genetics, and naming proposals are often far from ideal. We, however, suggest that the term “neuroacanthocytosis” should no longer be generally used and if so, only with appropriate understanding of its limitations. Further, we propose that chorea-acanthocytosis be renamed as “VPS13A disease” in accordance with its genetic etiology.